Cysteine protease inhibitors
    1.
    发明授权
    Cysteine protease inhibitors 有权
    半胱氨酸蛋白酶抑制剂

    公开(公告)号:US08198283B2

    公开(公告)日:2012-06-12

    申请号:US12986830

    申请日:2011-01-07

    CPC分类号: C07D491/048

    摘要: Compounds of the formula II: wherein R2 is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline; R3 is H, methyl or F; Rq is trifluoromethyl and Rq′ is H or Rq and Rq′ define keto; Q is a p-(C1-C6alkylsulphonyl)phenyl- or an optionally substituted 4-(C1-C6alkyl)piperazin-1-yl-thiazol-4-yl-moiety have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

    摘要翻译: 式II化合物:其中R2是亮氨酸的侧链,异亮氨酸,环己基甘氨酸,O-甲基苏氨酸,4-氟亮氨酸或3-甲氧基缬氨酸; R3是H,甲基或F; Rq是三氟甲基,Rq'是H或Rq,Rq'定义酮基; Q是对 - (C 1 -C 6烷基磺酰基)苯基 - 或任选取代的4-(C 1 -C 6烷基)哌嗪-1-基 - 噻唑-4-基 - 部分可用于治疗以不适当表达或活化为特征的疾病 组织蛋白酶K,例如骨质疏松症,骨关节炎,类风湿性关节炎或骨转移。

    Cysteine protease inhibitors
    3.
    发明授权
    Cysteine protease inhibitors 有权
    半胱氨酸蛋白酶抑制剂

    公开(公告)号:US08466158B2

    公开(公告)日:2013-06-18

    申请号:US13468787

    申请日:2012-05-10

    IPC分类号: A61K31/496

    CPC分类号: C07D491/048

    摘要: Compounds of the formula II: wherein R2 is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline; R3 is H, methyl or F; Rq is trifluoromethyl and Rq′ is H or Rq and Rq′ define keto; Q is a p-(C1-C6alkylsulphonyl)phenyl- or an optionally substituted 4-(C1-C6alkyl)piperazin-1-yl-thiazol-4-yl-moiety have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

    摘要翻译: 式II化合物:其中R2是亮氨酸的侧链,异亮氨酸,环己基甘氨酸,O-甲基苏氨酸,4-氟亮氨酸或3-甲氧基缬氨酸; R3是H,甲基或F; Rq是三氟甲基,Rq'是H或Rq,Rq'定义酮基; Q是对 - (C 1 -C 6烷基磺酰基)苯基 - 或任选取代的4-(C 1 -C 6烷基)哌嗪-1-基 - 噻唑-4-基 - 部分可用于治疗以不适当表达或活化为特征的疾病 组织蛋白酶K,例如骨质疏松症,骨关节炎,类风湿性关节炎或骨转移。

    PROTEASE INHIBITORS
    4.
    发明申请
    PROTEASE INHIBITORS 有权
    PROTEASE抑制剂

    公开(公告)号:US20120289519A1

    公开(公告)日:2012-11-15

    申请号:US13541519

    申请日:2012-07-03

    IPC分类号: A61K31/496 A61P19/02

    摘要: Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3; or R1 forms an ethynyl bond and R2 is H or optionally substituted C3-C6 cycloalkyl; R3 is (optionally substituted) C1-C3 alkyl or C3-C6 cycloalkyl; R4 is methyl or fluoro; m is 0-2; E is optionally substituted thiazolyl; A1 and A2 together define an optionally substituted piperazine or piperidine ring have utility in the treatment of osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

    摘要翻译: 式II化合物:其中R 1和R 2独立地是H,F或CH 3; 或R 1形成乙炔基,R 2为H或任选取代的C 3 -C 6环烷基; R3是(任选取代的)C 1 -C 3烷基或C 3 -C 6环烷基; R4是甲基或氟; m为0-2; E是任选取代的噻唑基; A1和A2一起限定任选取代的哌嗪或哌啶环可用于治疗骨质疏松症,骨关节炎,类风湿性关节炎或骨转移。

    Cysteine protease inhibitors
    5.
    发明授权
    Cysteine protease inhibitors 有权
    半胱氨酸蛋白酶抑制剂

    公开(公告)号:US07893067B2

    公开(公告)日:2011-02-22

    申请号:US12145987

    申请日:2008-06-25

    IPC分类号: A61K31/407 C07D491/04

    CPC分类号: C07D491/048

    摘要: Compounds of the formula II: wherein R2 is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline; R3 is H, methyl or F; Rq is trifluoromethyl and Rq′ is H or Rq and Rq′ define keto; Q is a p-(C1-C6alkylsulphonyl)phenyl- or an optionally substituted 4-(C1-C6alkyl)piperazin-1-yl-thiazol-4-yl- moiety have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

    摘要翻译: 式II化合物:其中R2是亮氨酸的侧链,异亮氨酸,环己基甘氨酸,O-甲基苏氨酸,4-氟亮氨酸或3-甲氧基缬氨酸; R3是H,甲基或F; Rq是三氟甲基,Rq'是H或Rq,Rq'定义酮基; Q是对(C 1 -C 6烷基磺酰基)苯基 - 或任选取代的4-(C 1 -C 6烷基)哌嗪-1-基 - 噻唑-4-基 - 部分可用于治疗以不适当表达或活化为特征的疾病 组织蛋白酶K,例如骨质疏松症,骨关节炎,类风湿性关节炎或骨转移。

    Protease Inhibitors
    6.
    发明申请
    Protease Inhibitors 有权
    蛋白酶抑制剂

    公开(公告)号:US20110039862A1

    公开(公告)日:2011-02-17

    申请号:US12739489

    申请日:2009-09-24

    摘要: Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3; or R1 forms an ethynyl bond and R2 is H or C3-C6 cycloalkyl which is optionally substituted with one or two substituents independently selected from methyl, CF3, OMe or halo; R3 is C1-C3 alkyl or C3-C6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R3 is C3-C6 cycloalkyl it may alternatively be gem substituted with fluoro; R4 is methyl or fluoro; m is 0, 1 or 2; E is a bond, or thiazolyl, optionally substituted with methyl or fluoro; A1 is CH or N, A2 is CR6R7 or NR6, provided at least one of A1 and A2 comprises N; R6 is H, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkyl-O—C1-C3 alkyl, or when A2 is C, R6 can also be C1-C4alkoxy or F; R7 is H, C1-C4 alkyl or F or a pharmaceutically acceptable salt, N-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

    摘要翻译: 式II化合物:其中R 1和R 2独立地是H,F或CH 3; 或R1形成乙炔基,R2是H或C3-C6环烷基,其任选地被一个或两个独立地选自甲基,CF 3,OMe或卤素的取代基取代; R 3是C 1 -C 3烷基或C 3 -C 6环烷基,当R 3是C 3 -C 6环烷基时,它们任选被一个或两个甲基和/或氟,三氟甲基或甲氧基取代,也可以被氟取代; R4是甲基或氟; m为0,1或2; E是任选被甲基或氟取代的键或噻唑基; A1是CH或N,A2是CR6R7或NR6,条件是A1和A2中的至少一个包括N; R6是H,C1-C4烷基,C1-C4卤代烷基,C1-C3烷基-O-C1-C3烷基,或当A2是C时,R6也可以是C1-C4烷氧基或F; R7是H,C1-C4烷基或F或其药学上可接受的盐,N-氧化物或其水合物,可用于治疗组织蛋白酶K不适当表达或活化的疾病,例如骨质疏松症,骨关节炎,类风湿性关节炎或骨骼 转移。

    CYSTEINE PROTEASE INHIBITORS
    7.
    发明申请
    CYSTEINE PROTEASE INHIBITORS 有权
    CYSTEINE PROTEASE抑制剂

    公开(公告)号:US20120220602A1

    公开(公告)日:2012-08-30

    申请号:US13468787

    申请日:2012-05-10

    CPC分类号: C07D491/048

    摘要: Compounds of the formula II: wherein R2 is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline; R3 is H, methyl or F; Rq is trifluoromethyl and Rq′ is H or Rq and Rq′ define keto; Q is a p-(C1-C6alkylsulphonyl)phenyl- or an optionally substituted 4-(C1-C6alkyl)piperazin-1-yl-thiazol-4-yl- moiety have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

    摘要翻译: 式II化合物:其中R2是亮氨酸的侧链,异亮氨酸,环己基甘氨酸,O-甲基苏氨酸,4-氟亮氨酸或3-甲氧基缬氨酸; R3是H,甲基或F; Rq是三氟甲基,Rq'是H或Rq,Rq'定义酮基; Q是对(C 1 -C 6烷基磺酰基)苯基 - 或任选取代的4-(C 1 -C 6烷基)哌嗪-1-基 - 噻唑-4-基 - 部分可用于治疗以不适当表达或活化为特征的疾病 组织蛋白酶K,例如骨质疏松症,骨关节炎,类风湿性关节炎或骨转移。

    CYSTEINE PROTEASE INHIBITORS
    9.
    发明申请
    CYSTEINE PROTEASE INHIBITORS 有权
    CYSTEINE PROTEASE抑制剂

    公开(公告)号:US20110105524A1

    公开(公告)日:2011-05-05

    申请号:US12986830

    申请日:2011-01-07

    CPC分类号: C07D491/048

    摘要: Compounds of the formula II: wherein R2 is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline; R3 is H, methyl or F; Rq is trifluoromethyl and Rq′ is H or Rq and Rq′ define keto; Q is a p-(C1-C6alkylsulphonyl)phenyl- or an optionally substituted 4-(C1-C6alkyl)piperazin-1-yl-thiazol-4-yl-moiety have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

    摘要翻译: 式II化合物:其中R2是亮氨酸的侧链,异亮氨酸,环己基甘氨酸,O-甲基苏氨酸,4-氟亮氨酸或3-甲氧基缬氨酸; R3是H,甲基或F; Rq是三氟甲基,Rq'是H或Rq,Rq'定义酮基; Q是对 - (C 1 -C 6烷基磺酰基)苯基 - 或任选取代的4-(C 1 -C 6烷基)哌嗪-1-基 - 噻唑-4-基 - 部分可用于治疗以不适当表达或活化为特征的疾病 组织蛋白酶K,例如骨质疏松症,骨关节炎,类风湿性关节炎或骨转移。

    Protease inhibitors
    10.
    发明授权
    Protease inhibitors 有权
    蛋白酶抑制剂

    公开(公告)号:US08426421B2

    公开(公告)日:2013-04-23

    申请号:US13541519

    申请日:2012-07-03

    IPC分类号: A61K31/496

    摘要: Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3; or R1 forms an ethynyl bond and R2 is H or optionally substituted C3-C6 cycloalkyl; R3 is (optionally substituted) C1-C3 alkyl or C3-C6 cycloalkyl; R4 is methyl or fluoro; m is 0-2; E is optionally substituted thiazolyl; A1 and A2 together define an optionally substituted piperazine or piperidine ring have utility in the treatment of osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

    摘要翻译: 式II化合物:其中R 1和R 2独立地为H,F或CH 3; 或R 1形成乙炔基,R 2为H或任选取代的C 3 -C 6环烷基; R 3是(任选取代的)C 1 -C 3烷基或C 3 -C 6环烷基; R4是甲基或氟; m为0-2; E是任选取代的噻唑基; A1和A2一起限定任选取代的哌嗪或哌啶环可用于治疗骨质疏松症,骨关节炎,类风湿性关节炎或骨转移。